Outlook Therapeutics, Inc. reported on November 13, 2025, that the FDA acknowledged their resubmission of the Biologics License Application for ONS-5010, which is now undergoing a two-month review with a goal date of December 31, 2025.
AI Assistant
OUTLOOK THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.